



ANDA 201971

ANDA APPROVAL

Mylan Pharmaceuticals Inc.
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504-4310
Attention: Julianne M. Foley
Director, Regulatory Affairs

Dear Madam:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on May 17, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Rasagiline Tablets, 0.5 mg and 1 mg.

Reference is also made to the tentative approval letter issued by this office on September 5, 2013, the complete response letter issued by this office on December 8, 2016, and to your amendment received on March 22, 2017.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is **approved**, effective on the date of this letter. The Office of Bioequivalence has determined your Rasagiline Tablets, 0.5 mg and 1 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Azilect Tablets, 0.5 mg and 1 mg, of Teva Pharmaceuticals USA (Teva). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

The RLD upon which you have based your ANDA, Teva's Azilect Tablets, 0.5 mg and 1 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
7,572,834 (the '834 patent)	December 5, 2026
7,815,942 (the '942 patent)	August 27, 2027

Your ANDA contains paragraph IV certifications to each of the patents¹ under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Rasagiline Tablets, 0.5 mg and 1 mg, under

¹ The agency notes that the '942 patent was submitted to the agency after submission of your ANDA. Litigation, if any, with respect to this patent would not create a statutory stay of approval.

this ANDA. You have notified the Agency that Mylan Pharmaceuticals Inc. (Mylan) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that no action for infringement was brought against Mylan within the statutory 45-day period.

In addition, you notified the Agency that Teva granted a selective waiver to Mylan with respect to the “three-year Hatch-Waxman” exclusivity associated with the RLD, as indicated in the Orange Book with the exclusivity code I-685. With this waiver, the Office of Generic Drugs is able to approve your ANDA for this use prior to the expiration of exclusivity. This exclusivity will expire on May 29, 2017.

With respect to 180-day generic drug exclusivity, we note that Mylan was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Rasagiline Tablets, 0.5 mg and 1 mg. Therefore, with this approval, Mylan is eligible for 180 days of shared generic drug exclusivity for Rasagiline Tablets, 0.5 mg and 1 mg. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). This exclusivity was triggered on January 2, 2017. Please submit correspondence to this ANDA informing the Agency of the date you begin commercial marketing.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

The Electronic Common Technical Document (eCTD) is CDER’s standard format for electronic regulatory submissions. Beginning May 5, 2017, ANDAs must be submitted in eCTD format and beginning May 5, 2018, drug master files must be submitted in eCTD format. Submissions

that do not adhere to the requirements stated in the eCTD Guidance will be subject to rejection.
For more information please visit: www.fda.gov/ectd.

Sincerely yours,

{See appended electronic signature page}

For Carol A. Holquist, RPh
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Priya
Shah

Digitally signed by Priya Shah
Date: 5/15/2017 01:20:51PM
GUID: 5256c7080002b0e78814870319c70608